Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.65 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30739951 | 1.00 | ESR2 (0.65) | ESR2NR1H2ABHD6TMEM97SIGMAR1 | |
| SCHEMBL2284685 | 0.96 | NR1H2 (0.61) | ESR2NR1H2ABHD6TMEM97SIGMAR1 | |
| SCHEMBL29883466 | 0.96 | NR1H2 (0.61) | ESR2NR1H2ABHD6TMEM97SIGMAR1 | |
| SCHEMBL1789713 | 0.93 | ESR2 (0.55) | ESR2NR1H2GPR119 | |
| SCHEMBL15878872 | 0.91 | ESR2 (0.51) | ESR2NR1H2ABHD6GPR119MAPK1 | |
| SCHEMBL29155326 | 0.85 | ESR2 (0.43) | ESR2TMEM97SIGMAR1ESR1 | |
| SCHEMBL3176570 | 0.84 | ABHD6 (0.47) | ESR2ABHD6TMEM97SIGMAR1ESR1 | |
| SCHEMBL14768550 | 0.83 | ESR2 (0.70) | ESR2NR1H2ABHD6TMEM97SIGMAR1 | |
| SCHEMBL29407529 | 0.83 | ESR2 (0.70) | ESR2NR1H2ABHD6TMEM97SIGMAR1 | |
| SCHEMBL168265 | 0.83 | ESR2 (0.70) | ESR2NR1H2ABHD6TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174615-A1 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-30 | — | — | US | disclosed |
| EP-4320101-A2 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | Revolution Medicines, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117412954-A | Synthesis of rapamycin analog compounds | 锐新医药公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| WO-2022216900-A2 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | Revolution Medicines, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2018-12-13 | — | — | US | disclosed |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2424861-A1 | INDOLE-2-CARBOXAMIDE DERIVATIVE | MSD K.K. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | MSD K.K. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010126164-A1 | INDOLE-2-CARBOXAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | HTR1F, HTR3C, HTR6 | ESR2 1065/4885NR1H2 311/4885ABHD6 1486/4885 |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | ESR2 2386/4885NR1H2 278/4885ABHD6 1322/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | ESR2 2593/4885NR1H2 637/4885ABHD6 2346/4885 |
| US-20240174615-A1 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | MLST8, MTOR, RICTOR | ESR2 2865/4885NR1H2 3344/4885ABHD6 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.